Donald Trump, Joe Biden

Trump Order Didn’t Reverse All of Biden’s Measures to Lower Drug Costs
President Donald Trump rescinded an executive order issued by former President Joe Biden aimed at finding new models for lowering drug costs. Trump's action didn't affect the caps on seniors' drug costs or Medicare price negotiations that Biden signed into law.
Fact Check: Insulin cap for Medicare unaffected by Trump order on prescription drug costs
A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest President Donald Trump has canceled the $35 insulin co-pay cap for certain Medicare programs.
Trump’s prescription drug executive order rollback didn’t quash all Biden-backed cost savings
The executive order, which Biden signed in October 2022, had not spurred any lower drug prices by the time Trump revoked it Jan. 20. The order directed the Health and Human Services Department secretary to consider "new health care payment and delivery models" for the Center for Medicare and Medicaid Innovation to test.
No, Trump Did Not Repeal Insulin Price Cap for Medicare Recipients
“Rescinding the cap on insulin at $35 only makes pharmaceutical richer and everyday Americans, including MAGA voters, seriously poorer,” Steven Bechloss—author of the Substack, America, America — posted to the Bluesky social media platform.
Trump Reverses Some Biden Drug Pricing Initiatives, Potentially Impacting Medicare Costs
Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.
What’s Trump Done on Prescription Drug Prices So Far – and What Might Be Next?
An early move by the president has raised questions about what direction his second-term policy on drug costs will take.
Where $2 prescription drug prices, Obamacare stand in Trump executive order onslaught
Trump stopped a program that had been in the works and was intended to give Medicare recipients access to more than 100 generic drugs for $2 a month, according to another executive order signed on Trump's first day in his new term.
Trump order signals shake-up in drug pricing innovation through Medicare and Medicaid
President Donald Trump’s Day One executive order rescinding Biden-era Medicare and Medicaid price innovation programs signals sweeping changes to the drug and treatment pricing agency within the Centers for Medicare and Medicaid Services and perhaps a substantive shake-up in two of the largest federal social welfare programs.
Townhall5dOpinion
The Biden Administration Left a Medicare Mess Behind — Now Trump Must Clean It Up
January, the Biden administration released its proposed Medicare Advantage rates in 2026. These are the rates that the ...
11Alive10d
Yes, Trump rescinded Biden's order to lower prescription drug costs for people on Medicare and Medicaid
to develop and test ways to lower drug prices for people on Medicare and Medicaid. Since former-President Joe Biden's ...
Newsweek on MSN5d
Donald Trump's Medicare Executive Order Explained
Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.
The Washington Post on MSN12d
Neera Tanden worries the election was ‘bait-and-switch’ on health care
Biden’s domestic policy adviser says Trump avoided pledges to overhaul the Affordable Care Act and other health programs — ...
The Good and the Bad of Joe Biden’s Presidency
As President Joe Biden gets ready to leave office, we consider his accomplishments, failures, and what his legacy will be.
Trump's Day One actions reversed Biden-era health policies, including efforts to expand ObamaCare
President Trump is rolling back Biden healthcare policies, such as expansions to the Affordable Care Act – a move Democrats ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Healio2d
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...